StocktoriaQuince Therapeutics, Inc. QNCX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
3/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$58.1M | -$57.3M | -$34.6M | -$52.0M | -$90.3M |
| Net income | -$84.0M | -$56.8M | -$31.4M | -$51.7M | -$89.9M |
| Operating cash flow | -$41.4M | -$31.9M | -$18.3M | -$44.0M | -$62.9M |
| Free cash flow | -$41.8M | -$32.2M | -$18.5M | -$44.2M | -$63.1M |
| Total assets | $93.5M | $114.5M | $167.9M | $103.9M | $133.2M |
| Total liabilities | $129.2M | $84.3M | $82.8M | $3.3M | $14.6M |
| Shareholders' equity | -$35.7M | $30.1M | $85.1M | $100.6M | $118.6M |
| Ratios | |||||
| Return on assets | -89.8% | -49.6% | -18.7% | -49.7% | -67.5% |
| Return on equity | 235.1% | -188.5% | -36.9% | -51.4% | -75.8% |
| Debt / equity | -0.00× | 0.48× | 0.16× | 0.00× | — |
| Current ratio | 0.53 | 6.05 | 8.09 | 30.55 | 7.85 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001662774 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.